{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/6a13c15d-181a-4a2e-a662-739d0e7f731a/6615bf72ecab3b0016241572?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Can WeightWatchers survive the Wegovy era?","description":"<p>WeightWatchers is struggling. Launched in the early 1960s, the brand grew by helping members shed pounds through behavioural change programmes. Then, GLP-1 anti-obesity drugs hit the market, long-time spokesperson and board member Oprah Winfrey announced her departure, and the company’s credit rating was downgraded. FT reporter Anna Mutoh examines whether WeightWatchers’ latest strategy can produce the turnaround investors are hoping for.&nbsp;&nbsp;</p><p><br></p><p>Clip from Lionsgate Television</p><p>- - - - - - - - - - - - - - - - - - - - - - - - - -&nbsp;</p><p><strong>For further reading:</strong></p><p><a href=\"https://www.ft.com/content/c117e5f8-48af-460f-bda8-a95cf13ba3dc\" rel=\"noopener noreferrer\" target=\"_blank\">WeightWatchers faces an era when weight loss comes in a syringe</a></p><p><a href=\"https://www.ft.com/content/b5b4cfc8-1d20-47a6-840f-ff84f0e067f7\" rel=\"noopener noreferrer\" target=\"_blank\">Behold the Ozempic effect on business</a>&nbsp;</p><p><a href=\"https://www.ft.com/content/864631da-24d2-4d18-96b2-d2cb450edd5b\" rel=\"noopener noreferrer\" target=\"_blank\">The race to develop the next generation of weight-loss drugs</a></p><p>- - - - - - - - - - - - - - - - - - - - - - - - - -&nbsp;</p><p>On X, follow Anna Mutoh (<a href=\"https://twitter.com/anna_mutoh?lang=en\" rel=\"noopener noreferrer\" target=\"_blank\">@anna_mutoh</a>) and Michela Tindera (<a href=\"https://twitter.com/mtindera07\" rel=\"noopener noreferrer\" target=\"_blank\">@mtindera07</a>), or follow Michela on LinkedIn for updates about the show and more.&nbsp;</p><p><br></p><p><a href=\"https://www.ft.com/content/aad3a9f7-6420-4824-94f5-cb91d0bb1189\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>Read a transcript of this episode on FT.com</strong></a></p>","author_name":"Financial Times"}